LY 3938577
Alternative Names: LY-3938577Latest Information Update: 09 Aug 2024
At a glance
- Originator Eli Lilly and Company
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Type 2 diabetes mellitus
Most Recent Events
- 28 Jun 2024 Eli Lilly and Company completes a phase trial in Type 2 diabetes mellitus in USA (SC) (NCT06132126)
- 15 May 2024 Phase-I clinical trials in Type 2 diabetes mellitus in Germany (IV) (NCT06280703)
- 28 Feb 2024 Eli Lilly and Company plans a phase I trial for Type 1 diabetes mellitus in Germany in May 2024 (IV) (NCT06280703)